Hoyos Rocio Martin 4

4 · Atrium Therapeutics, Inc. · Filed Apr 22, 2026

AI-generated summary of this filing

Updated Apr 22, 2026

Atrium Therapeutics (RNA) CSO Rocio Hoyos Martin Receives Awards

What Happened

Rocio Hoyos Martin, Chief Strategy Officer of Atrium Therapeutics (RNA), received equity awards on April 20, 2026: 30,000 restricted stock units (RSUs) and 60,000 derivative awards (stock option-style), each granted at $0.00 (no cash exchanged). These are compensation grants, not open-market purchases or sales.

Key Details

Transaction date: 2026-04-20; Form 4 filed 2026-04-22 (appears timely).
Award amounts and price: 30,000 RSUs @ $0.00; 60,000 derivative awards (options) @ $0.00.
Shares owned after transaction: Not reported in this filing.
Vesting (from footnotes):
- RSUs (30,000): 25% vest on March 20, 2027; remaining RSUs vest in three substantially equal annual installments thereafter (subject to continued service).
- Derivative awards/options (60,000): 25% vest on March 20, 2027; remaining shares vest in 36 substantially equal monthly installments thereafter (subject to continued service).
No 10b5-1 plan, tax-withholding, or late-filing flag disclosed in this filing.

Context

RSUs: each RSU is a contingent right to receive one share upon vesting (no immediate shares received).
Derivative awards/options: represent the right to acquire shares if/when vested and exercised; they are not the same as owning shares today.
These grants are typical executive compensation and do not by themselves indicate a buying or selling decision in the open market.

Form 4

Period: 2026-04-20

Chief Strategy Officer

Transactions

Award
Common Stock
[F1]
2026-04-20+30,000→ 46,660 total
Award
Stock Option (Right to Buy)
[F2]
2026-04-20+60,000→ 60,000 total
Exercise: $14.30Exp: 2036-04-20→ Common Stock (60,000 underlying)

Footnotes (2)

[F1]Represents an award of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Twenty-five percent (25%) of the RSUs shall vest on March 20, 2027, with the remaining RSUs vesting in three (3) substantially equal yearly installments each year thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date.
[F2]Twenty-five percent (25%) of the shares underlying this option shall vest and become exercisable on March 20, 2027, with the remaining shares vesting in thirty-six (36) substantially equal monthly installments each month thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date.

Signature

/s/ Brendan Winslow, Attorney-in-Fact|2026-04-22

1 file